Values First Advisors Inc. Has $950,000 Position in Guardant Health, Inc. (NASDAQ:GH)

Values First Advisors Inc. raised its holdings in Guardant Health, Inc. (NASDAQ:GH) by 15.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 35,135 shares of the company’s stock after acquiring an additional 4,604 shares during the quarter. Values First Advisors Inc.’s holdings in Guardant Health were worth $950,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. CWM LLC raised its position in shares of Guardant Health by 137.1% in the third quarter. CWM LLC now owns 984 shares of the company’s stock valued at $29,000 after purchasing an additional 569 shares during the period. BluePath Capital Management LLC acquired a new stake in Guardant Health during the third quarter worth $35,000. Acadian Asset Management LLC acquired a new stake in Guardant Health during the first quarter worth $37,000. Captrust Financial Advisors boosted its stake in Guardant Health by 33.2% during the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock worth $44,000 after buying an additional 271 shares in the last quarter. Finally, Belpointe Asset Management LLC boosted its stake in Guardant Health by 33.3% during the first quarter. Belpointe Asset Management LLC now owns 3,049 shares of the company’s stock worth $71,000 after buying an additional 761 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Kumud Kalia purchased 2,187 shares of Guardant Health stock in a transaction on Monday, March 18th. The stock was purchased at an average price of $17.82 per share, with a total value of $38,972.34. Following the transaction, the insider now directly owns 12,722 shares in the company, valued at approximately $226,706.04. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 6.20% of the stock is owned by company insiders.

Guardant Health Price Performance

Shares of GH stock traded up $2.67 on Friday, reaching $20.63. The company had a trading volume of 5,569,146 shares, compared to its average volume of 1,669,355. The company has a debt-to-equity ratio of 7.18, a quick ratio of 6.24 and a current ratio of 6.54. The company has a 50-day moving average of $20.56 and a 200-day moving average of $24.44. Guardant Health, Inc. has a 12 month low of $16.92 and a 12 month high of $41.06.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). Guardant Health had a negative return on equity of 301.94% and a negative net margin of 85.02%. The business had revenue of $155.05 million for the quarter, compared to the consensus estimate of $151.71 million. As a group, equities research analysts expect that Guardant Health, Inc. will post -3.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Guggenheim assumed coverage on shares of Guardant Health in a research note on Thursday, December 14th. They issued a “neutral” rating on the stock. The Goldman Sachs Group reduced their price target on shares of Guardant Health from $43.00 to $37.00 and set a “buy” rating on the stock in a research report on Monday, January 29th. Piper Sandler reduced their price target on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, February 26th. JPMorgan Chase & Co. reduced their price target on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Finally, Wolfe Research assumed coverage on Guardant Health in a report on Wednesday, December 13th. They set a “peer perform” rating for the company. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.30.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.